Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system, has appointed Darlene Deptula-Hicks as Chief Financial Officer. An accomplished…
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel…
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today shared more data on the challenges Americans are facing when trying to access…
Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, is proud to announce the appointment of Howard Hechler as Chief…
AstraZeneca today announced a $3.5 billion investment in the United States to expand the company’s research and manufacturing footprint by the end of 2026. This includes $2 billion in new…
QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy business unit. The unit’s first achievement is the opening of a new Leukopak…
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create…
Business Leaders and Industry Experts Join Top Policymakers to Address Pivotal Issues in Health Globally at the Milken Institute 2024 Future of Health Summit The Milken Institute 2024 Future of Health…
Enveda, a biotechnology company using AI to translate nature into new medicines, announced today that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application…
Reverb Therapeutics, a leader harnessing the body’s immune system and cytokine signaling to treat life-threatening diseases, announced it has launched a collaboration with Royalmount Laboratories, based in Montreal, as Reverb…
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company’s…
VIVOLTA, the medical electrospinning solutions provider, has signed a long-term partnership with Neurochase, the CNS (central nervous system) delivery platform specialist, to manufacture electrospun micro-catheters to deliver advanced therapies to…